Voyager Therapeutics, Inc. Common Stock VYGR
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-08T09:15:42.953Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-12-18
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T22:24:26.667495089Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-08T09:15:14.287781+00:00
Voyager Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 3.19 | 717.4% | 68.0% | |||
| 25Δ | 3.31 | 661.7% | 61.1% | |||
| 30Δ | 3.44 | 606.0% | 54.2% | |||
| 35Δ | 3.56 | 550.3% | 47.3% | |||
| 40Δ | 3.95 | 307.4% | 134.0% | 3.69 | 494.6% | 40.5% |
| 45Δ | 3.80 | 342.0% | 131.5% | 3.82 | 438.9% | 33.6% |
| 50Δ | 3.66 | 376.6% | 128.9% | 3.94 | 383.2% | 26.7% |
| 55Δ | 3.52 | 411.2% | 126.4% | 4.09 | 345.8% | 21.8% |
| 60Δ | 3.37 | 445.7% | 123.9% | 4.26 | 324.6% | 18.5% |
| 65Δ | 3.23 | 480.3% | 121.3% | 4.43 | 303.5% | 15.2% |
| 70Δ | 3.09 | 514.9% | 118.8% | 4.61 | 282.3% | 11.9% |
| 75Δ | 4.78 | 261.1% | 8.6% | |||
| 80Δ | 4.95 | 240.0% | 5.3% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.19
- IV
- 717.4%
- B/E move
- 68.0%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.31
- IV
- 661.7%
- B/E move
- 61.1%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.44
- IV
- 606.0%
- B/E move
- 54.2%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.56
- IV
- 550.3%
- B/E move
- 47.3%
40Δ
- Pseudo strike
- 3.95
- IV
- 307.4%
- B/E move
- 134.0%
- Pseudo strike
- 3.69
- IV
- 494.6%
- B/E move
- 40.5%
45Δ
- Pseudo strike
- 3.80
- IV
- 342.0%
- B/E move
- 131.5%
- Pseudo strike
- 3.82
- IV
- 438.9%
- B/E move
- 33.6%
50Δ
- Pseudo strike
- 3.66
- IV
- 376.6%
- B/E move
- 128.9%
- Pseudo strike
- 3.94
- IV
- 383.2%
- B/E move
- 26.7%
55Δ
- Pseudo strike
- 3.52
- IV
- 411.2%
- B/E move
- 126.4%
- Pseudo strike
- 4.09
- IV
- 345.8%
- B/E move
- 21.8%
60Δ
- Pseudo strike
- 3.37
- IV
- 445.7%
- B/E move
- 123.9%
- Pseudo strike
- 4.26
- IV
- 324.6%
- B/E move
- 18.5%
65Δ
- Pseudo strike
- 3.23
- IV
- 480.3%
- B/E move
- 121.3%
- Pseudo strike
- 4.43
- IV
- 303.5%
- B/E move
- 15.2%
70Δ
- Pseudo strike
- 3.09
- IV
- 514.9%
- B/E move
- 118.8%
- Pseudo strike
- 4.61
- IV
- 282.3%
- B/E move
- 11.9%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.78
- IV
- 261.1%
- B/E move
- 8.6%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.95
- IV
- 240.0%
- B/E move
- 5.3%
Options history
No recorded observations
Biotechnology
WHWK
Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. The company is headquartered in…
More →WVE
Wave Life Sciences Ltd., a clinical-stage genetic medicine company, designs, optimizes and produces new stereopure oligonucleotides through PRISM, a drug discovery and development…
More →XBIT
XBiotech Inc., a biopharmaceutical company, discovers, develops and markets True Human monoclonal antibodies for the treatment of various diseases. The company is headquartered in…
More →XENE
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat patients with neurological disorders in Canada. The company…
More →XFOR
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of new therapies for the treatment of back…
More →XNCR
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed to treat cancer patients…
More →